Ultragenyx Pharmaceutical (RARE) Accumulated Depreciation & Amortization (2013 - 2025)

Ultragenyx Pharmaceutical (RARE) has 13 years of Accumulated Depreciation & Amortization data on file, last reported at $136.0 million in Q4 2025.

• Quarterly Accumulated Depreciation & Amortization rose 21.43% year-over-year to $136.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $136.0 million (up 21.43% YoY) and the FY2025 annual result came in at $136.0 million, up 21.43% from the prior year.
• Accumulated Depreciation & Amortization climbed to $136.0 million in Q4 2025 per RARE's latest filing, from $112.0 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $136.0 million in Q4 2025 and bottomed at $50.0 million in Q4 2021.
• The 5-year median for Accumulated Depreciation & Amortization is $83.4 million (2023), against an average of $89.0 million.
• The widest annual swing landed in 2024, when Accumulated Depreciation & Amortization soared 34.29%; it then climbed 21.43% in 2025.
• Tracing RARE's Accumulated Depreciation & Amortization over 5 years: stood at $50.0 million in 2021, then gained by 26.67% to $63.4 million in 2022, then surged by 31.59% to $83.4 million in 2023, then soared by 34.29% to $112.0 million in 2024, then climbed by 21.43% to $136.0 million in 2025.
• Per Business Quant, the three latest RARE Accumulated Depreciation & Amortization figures stand at $136.0 million (Q4 2025), $112.0 million (Q4 2024), and $83.4 million (Q4 2023).

Peer Comparison